Success Metrics

Clinical Success Rate

86.4%

Based on 19 completed trials

Completion Rate

86%(19/22)

Active Trials

0(0%)

Results Posted

11%(2 trials)

Terminated

3(13%)

Phase Distribution

Ph phase_1

30%

Ph phase_3

Ph not_applicable

Ph phase_2

57%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution23 total trials

Phase 1Safety & dosage

7(30.4%)

Phase 2Efficacy & side effects

13(56.5%)

Phase 3Large-scale testing

2(8.7%)

N/ANon-phased studies

1(4.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

86.4%

19 of 22 finished

Non-Completion Rate

13.6%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(19)

Terminated(3)

Other(1)

Detailed Status

Completed19

Terminated3

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

86.4%

Most Advanced

Phase 3

Trials by Phase

Phase 17 (30.4%)

Phase 213 (56.5%)

Phase 32 (8.7%)

N/A1 (4.3%)

Trials by Status

completed1983%

unknown14%

terminated313%

Recent Activity

0 active trials

Showing 5 of 23

completedphase_2

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

NCT00019396

completedphase_3

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

NCT01989572

completedphase_2

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

NCT00089063

completedphase_2

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

NCT00003222

completedphase_2

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

NCT00031733

View all 23 trials

Clinical Trials (23)

Showing 20 of 23 trialsScroll for more

NCT00019396Phase 2

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

Completed

NCT01989572Phase 3

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

Completed

NCT00089063Phase 2

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Completed

NCT00003222Phase 2

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Completed

NCT00031733Phase 2

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

Completed

NCT00006113Phase 2

Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma

Terminated

NCT00003339Phase 2

Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma

Completed

NCT00005841Phase 1

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Terminated

NCT00025181Phase 1

Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery

Completed

NCT00003274Phase 2

Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery

Completed

NCT00085189Phase 2

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Completed

NCT00334776Phase 2

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Completed

NCT00037037Phase 1

Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma

Unknown

NCT00003792Phase 1

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Completed

NCT00003362Phase 2

Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma

Completed

NCT00019383Phase 2

Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma

Completed

NCT00005633Phase 1

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Completed

NCT00020358Phase 2

Vaccine Therapy in Treating Patients With Melanoma

Completed

NCT00003229Phase 1

Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal

Completed

NCT00003665Phase 1

Vaccine Therapy in Treating Patients With Stage IV Melanoma

Completed

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 23